350 FIFTH AVENUE, NEW YORK, NY
Annual Report to Security Holders
FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals Enters $100 Million Sales Agreement with Cantor Fitzge...
Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Other Events
Changes in Board, Management or Compensation
FY 2024
Q3
Q2
Q1
Tender Offer Statement by Issuer
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement